随着减重药巨头诺和诺德重磅GLP-1类药物司美格鲁肽在中国的核心分子专利即将于3月到期，一大批中国本土的司美格鲁肽仿制药正在获批路上。据公开信息，目前国内市场上包括九源基因、丽珠集团、华东医药、齐鲁制药、正大天晴在内的十多家本土制药公司的司美格鲁肽仿制药有望在不久的将来上市，还有十余款处于三期临床，一场价格大战即将席卷。一位内分泌专家表示，随着更多仿制药的上市，减重药很快就会迎来“白菜价”时代。（第一财经）
YouGov表示，今年稍晚將重新進行調查，以再次檢驗這個主題。
。一键获取谷歌浏览器下载对此有专业解读
Must achieve = 99% accuracy on 10,000 random test pairs (held-out, fixed seed)
It is not an easy task. Chelsea briefly thought they had their rising star when they hired Graham Potter in September 2022, only for his reign to end after seven months. Now there is hope that Liam Rosenior can become Chelsea’s answer to Arteta. Rosenior is young, confident, talented and a little unconventional in the way he presents himself. It is early days but the 41-year-old has made an encouraging start, winning eight of his first 12 games, and has transmitted enough authority to keep jibes about his inexperience at bay so far.